congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
Poster
Quizartinib
SOHO 2024 Annual Meeting | September 4-7, 2024
QuANTUM-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction and consolidation is associated with improved overall survival in newly diagnosed FLT3-ITD+ AML patients
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Poster
Quizartinib
SOHO 2024 Annual Meeting | September 4-7, 2024
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Oral
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia who received continuation therapy
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
QuANTUM-First: Patient-reported outcomes in newly diagnosed Italicize FLT3-ITD+ acute myeloid leukemia patients receiving standard chemotherapy plus quizartinib or placebo
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
Valemetostat for patients with relapsed/refractory peripheral T-cell lymphomas: The phase 2 VALENTINE-PTCL01 trial
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
Valemetostat monotherapy in patients with relapsed/refractory non-hodgkin lymphomas: Primary results from a phase 1 trial